## Mortality and predictors of Chronic Kidney Diseases (CKD) in 1

# selected dialysis centers in Addis Ababa, Ethiopia

- 3 Beza Zewdu Desta<sup>1</sup>, Behailu Tariku Derseh<sup>2</sup>, Abel Fekadu Dadi<sup>3, 4</sup>
- <sup>1</sup> Ethiopian Food, Medicine Administration and Health care Authority 4
- 5 <sup>2</sup> Departments of Public Health, Asrat Woldeyes Health Sciences Campus, Debre Berhan
- 6 University, Ethiopia
- 7 <sup>3</sup> Menzies School of Health Research, Charles Darwin University, Darwin, Australia
- 8 <sup>4</sup> Departments of Epidemiology and Biostatistics, College of Medicine and Health
- 9 Sciences, University of Gondar, Gondar, Amhara, Ethiopia
- 10 Corresponding author: Beza Zewdu Desta: bezazewdu23@gmail.com
- 11

2

- Email: 12
- 13 Behailu Tariku Derseh: minastariku@gmail.com
- 14 Abel Fekadu Dadi: fekten@vahoo.com

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

# 15 Abstract

Background: Chronic Kidney Disease (CKD) affects 10-15% of the population
worldwide. The number of dialysis patients is steadily rising in Ethiopia. Chronic
hemodialysis patients experience high rates of mortality; however, data is lacking in
Ethiopia. We explored the mortality and its driving factors in selected dialysis center in
Addis Ababa

21 **Method:** we retrospectively followed a group of End-Stage Renal Disease patients on 22 hemodialysis from 2016 to2020 in St. Paul Millennium Medical College (SPMMC), 23 Zewditu Memorial Hospital (ZMH), and Menellik II Hospital. We fitted Kaplan Meier 24 analysis to estimate the one and five year's survival probability of these patients and 25 Cox Proportional regression analysis to model the predictors of mortality at p value 26  $\leq 0.05$ .

27 **Result:** We analyzed a data of (139) patients under follow up. The mean age (± SD) of 28 the patients was 36.8 (±11.95) years. Twenty-four (17%) of the patients died at the end 29 of follow-up. The median survival time was 46.2 months (95% CI: 41.8, 50.5). The one 30 and five-year's survival probability of these patients was 64.8% and 18.7%. 31 respectively. Our analysis showed that patients with hypertension (AHR = 4.33; 95% CI: 32 1.02, 34.56), cardiac complication (AHR = 4.69; 95% CI: 1.32, 16.8), and infection during 33 dialysis (AHR = 3.89; 95% CI: 1.96, 13.8) were more likely to die. 34 **Conclusion:** The survival status of hemodialysis patients in three was low. Preventing

and treating comorbidities and complication during dialysis would reduce mortality of
 CKD patients.

37 **Keywords**: Kaplan Meier estimate, Incidence, Kidney failure, Survival analysis

# 38 Introduction

39 Chronic kidney disease (CKD) is a major public health problem that challenging health 40 system around the world(1). Chronic Kidney disease (CKD) is a progressive loss of 41 kidney function over a period of months or years. Professional guidelines classified the 42 severity of CKD in five stages. A clinically significant Stage 5 CKD or end-stage renal 43 disease is the most deliberating stage in which the patient should get Renal 44 Replacement Therapy(RRT) (2).

- A death associated with CKD has nearly be doubled worldwide between 1990 and
  2010 and was the 18 highest cause of death in 2010 (3). It is estimated that by 2030
  more than 70% of patients with end-stage renal disease will be living in low-income
  countries (4).
- Renal replacement therapy (RRT) is the mainstay of care for patients with an end stagerenal disease(ESRD) to reduce mortality and morbidity (5).
- 51 Patients with end-stage renal diseases (ESRD) are unable to sustain life without dialysis 52 support(6). That would last about 3 to 4 hours a week. The duration of each session 53 depends on how well the patient's kidneys work, and how much fluids weight the 54 patient has gained between treatments (6). There are three main types of vascular 55 accesses (VA) used in HD treatment: Arterio-Venous Fistula (AVF), Synthetic Arterio 56 Venous Graft (AVG), and Central Venous Catheter (CVC) (7). All types of VA have their 57 own risks and expensive. The clinical practice guidelines recommend, AVF as first 58 choice because of its reduced associated complications, morbidity, and mortality 59 compared with the AVG and CVC(8).
- Although there is limitation of data about prevalence of CKD, few studies indicate that renal disease has become a significant public health problem in Ethiopia. A cross sectional study showed that the prevalence of CKD in Ethiopia is estimated to be 12.2% and increased in the last few years following an increasing prevalence of diabetes and hypertension. The prevalence of CKD is as high as 41.0% in age <35 years and 62% in males (9).
- The high rate of mortality among dialysis patients after initiation of the therapy is
  attributed to factors such as demographic, comorbidities, blood markers such as
  albumin and hemoglobin, and type of vascular access (10)

69 Duration of dialysis per session, hypertension, and infection status significantly affect

- 70 the survival rate of ESRD. (11).
- 71 A study on survival pattern of hemodialysis patient in Ethiopia shows that 45.1 % of
- 72 death occurs during dialysis treatment and 23.1 % of the patient died within the first 90
- 73 days of initiation of dialysis, while only 42.1% of the patients survive more than a year.
- 74 Septicemia (34.1%), cardiovascular disease (29.3%) and uses of the catheter as
- vascular access was associated with a short and long term survival of patients treated
- 76 with hemodialysis (5).
- 77 There is limited data reporting mortality and its predictors among chronic hemodialysis
- 78 kidney patients that we intended to investigate in this study.

# 79 Methodology

# 80 Study setting and period

We analyzed a retrospectively recorded data of patients enrolled in a maintenance
hemodialysis in three hospitals in Addis Ababa (St. Paul Millennium Medical College
(SPMMC), Zewditu Memorial Hospital (ZMH), and Menelik II) from 1<sup>st</sup>January 2016 to
30<sup>th</sup> December 2020.

- Addis Ababa has a population size of 3,435,028 of whom 1,809,577 are females (12).There are 13 publics and 34 privates hospitals in the centers providing different public health services.
- We included all chronic kidney patients age 18 years and above who were onhemodialysis for End-Stage Renal Disease during the study period.
- We excluded: (1) Patients who starts hemodialysis for acute renal failure or patients who started dialysis on an emergency basis or acute dialysis (with the duration from first to last dialysis being less than 30 days); (2) those with incomplete medical record/charts for important variables; and (3) alive patients transferred into COVID- 19 center with their medical cards as these patients had restricted access.

#### **Outcome of interest** 95

96 The outcome is death of patients happening during the time of hemodialysis and we 97 both interested in modeling the mortality and time. Right censored patients were those 98 alive, default, and transferred during the time of follow up. The start of the follow-up 99 was the time the patient started maintenance hemodialysis. We calculated an incidence 100 rate by considering the time of follow-up of each patient contribute to the exposure 101 time.

#### **Covariates** 102

103 We did a literature review to identify the potential risk factors associated with death. 104 The covariates included: (1) Sociodemographic such as age, sex, marital status, 105 residence; (2) weight in kg, comorbidities such as hypertension, diabetes mellitus, 106 cancer, chronic kidney disease-mineral and bone disorder (CKD-MBD), types of vascular 107 access for dialysis (AV Fistula, Grift, Catheter); (3) cardiovascular disease such as 108 coronary artery disease (CAD), cardiac arrhythmia, cardiac failure, cardiac valvular 109 disease, pericardial disease, cardiomyopathy, and congenital heart disease; (4) biochemical profile of the patients such as Serum levels of hemoglobin, creatinine, 110 albumin, Phosphorus; (5) duration of dialysis per season and frequency of dialysis per 111 112 week.

#### 113 Data source

We extracted the required data from medical records and hemodialysis registration 114 books using a pretested data extraction form. The investigator further checked for the 115 116 validation and completeness of the extracted data. The variables included in this study were recorded in an Excel file. Missing values for important variables were completed 117 118 by reviewing clinical notes and reports available in the selected dialysis center. Trained 119 two Masters of Public Health Students and two Bachelor of nursing from each hospital, 120 and one supervisor were involved in the data extraction and validation. Both supervisor 121 and data collectors were trained for two days on how to extract data, what to be 122 extracted and to make them internalize the context of each question in the data 123 extraction form.

## 124 Data analysis

We entered the extracted data into Epi data and exported to SPSS for further analysis.
We used mean or median and standard deviation to present numeric data and
frequencies and percentages to present a categorical data.

128 We computed the person-time of follow-up from the date of starting hemodialysis to 129 death, loss to follow-up, or the end of the study. We calculated the Incidence rate of death by dividing the number of deaths among CKD patients occurring by person-130 131 months of follow-up. We used actuarial life table to estimate survival after initiation of 132 hemodialysis; and the Kaplan-Meier test to estimate the probability of death and the 133 median time to death after initiation of hemodialysis. We did log-rank test to compare a 134 time to death between different covariates. We checked assumption of proportional 135 hazard model using the Log (-log (St)) plots and tests. We used the Cox proportional 136 hazard model to determine the probability of death after initiation of hemodialysis 137 adjusting for confounding factors. We excluded covariates that violate the assumption 138 of cox proportional hazard model from the analysis. All statistically significant variables having a p-value  $\leq 0.25$  in the bivariate analysis were adjusted in the final model. We 139 estimated the crude and adjusted hazard ratio (HR) and its 95% confidence interval (CI) 140 141 were estimated to identify and report significant predictors of death at p-value < 0.05.

# 142 **Results**

- 143 We found total of 139 chronic dialysis patients who started a dialysis between January
- 144 1, 2016, and December 30, 2020.

## 145 Socio demographic characteristic of the patients

- Table 1 presents the characteristics of patients included in this study. Slightly above half
  of the patients were males 88 (63.3%). The mean (±SD) age at dialysis initiation was
  36.81(±11.50) years and more than half were in younger age category (18-34 years)
  (show table 1).
- 150 Majority of the patients 102(73.4%) were living in Addis Ababa while the rest 26.6 %
- 151 (37) came to Addis for treatment from different regions of Ethiopia(show table 1).

## **152 Baseline characteristics of the patients**

- 153 The mean (±SD) of systolic blood pressure was 143.25 mmHg (±22.063) at the initiation
- 154 of dialysis. The mean of blood pressure at the last session of dialysis was 142.10
- 155 (±19.083 mmHg). The mean (±SD) weight of the patients at dialysis initiation of dialysis
- 156 was 55.54 kg (show table 2).

### **157** Treatment modality

- Most of the patients (89.2%) had three sessions of dialysis per week. Duration of each
  session ranged between three to four hours. Most of the patients 121(87.1%) had four
  hours of stay in dialysis.
- 161 More than half (63.3%) of the hemodialysis patients were taking their treatment by 162
- 162 Arteriovenous Fistula (AVF) followed by catheter (AVC) 36%.
- About more than 80% of the patients were given some form of medication for complications of CKD and hemodialysis treatment and 82.2% of the patient were taking Erythropoietin (EPO). Twenty -four (17.3 %) of the patients had been given a blood transfusion at least once during their time on dialysis. The most common causes of ESRD were hypertension (48.2%), diabetes mellitus (6.5%), Glomerulonephritis (6.5%), Renal Stone (2.2 %) and 36.7% of the ESRD patients had unknown etiology ( show table 4 and 5).

## 170 Comorbidity and complication

171 Some forms of comorbidities were occurred in 78(56.1%) of the patients. 172 Cardiovascular complication was the most common comorbid complication recorded in 173 53.2% of the patients as moderate-severe mitral regurgitation and diastolic 174 dysfunction. Seventy-eight (56.1%) of the patients were developed different types of 175 infections sometimes in their course of treatment. For example, Hypotension occurred 176 in (36.0%) of the patients at least once during the period of dialysis (show table 4).

## 177 Survival status of patients on hemodialysis

About 24 (17%) patients died and the rest 115(83%) were censored during the follow
up. The sample included 88 male patients of which 15(17%) were died and 51 females
of which nine were (17.65%) died. Twenty four patients were died during the first 60
months follow-up. Among these, 10 and 4 were dead during the first and second six

182 months of follow-up, respectively. The median survival time was 46.2 months and the

183 overall survival rate was86% at one year and 70% at five years.

### **184 Predictors of mortality**

Hypertension, cardiovascular complication, infection, and types of vascular access were
turned-out to predict the mortality in adjusted model (show figure 1 and table 7). As
such being hypertensive increased the risk of mortality by 4.3 times (95%CI: 1.0218.43).

- Patients with cardiovascular complication had a 4.7 (95%CI: 1.32-16.76) times higher risk of mortality. The risk of mortality among patients using Arterio-Venous Graft and temporary venous catheter were 19.57 (95%CI: 2.01-190.74) and 3.84(95%CI: 1.40, 10.50) times higher than those patients using Arterio-Venous Fistula. Furthermore, a risk of mortality was 3.59 (95%CI: 1.98-13.05) times higher among patients with
- 194 comorbid infection.

# 195 **Discussion**

Dialysis remains the priority intervention for patients with advanced CKD as there are limited organs for transplantation and excesses risks associated with the transplantation for most of patients worldwide. Dialysis prolong and improve quality of life of patients with kidney failure, and this needs a continues evaluation of the procedure to improve treatment outcomes. We aimed to conduct this secondary data analysis as an evaluation and to inform clinicians about factors that trigger the mortality of patients in dialysis centers in Addis Ababa.

203 The median follow-up time of the patients was 46.2 months and its consistent with 204 patients in Adama hospital that estimated to be 43 months(13). Furthermore, the 205 survival rate of patients under follow up was 70% at 5-years and 86% at 1-years which 206 relatively the same with a similar study reported elsewhere which reported to be 80%(14). Another study from Brazil reported a survival rate of 84.7% in the first and 207 208 63.3% in the five years of treatment (15). The main reason for the discrepancy might be 209 the low accessibility and cost of the service in Ethiopia. The lower long-term survival 210 rate of the patients could be attributed to in that undergoing dialysis is very low and 211 can be attributable to medical conditions that we have identified including; types of 212 vascular access type, hypertension, infection status, and cardiac complications.

213 Patients with cardiovascular complications had around four times increased risk of mortality compared to those patients with no cardiac complications. In another way, the 214 215 mean survival months of patients with cardiac complication was 14 months lower. This 216 result is similar to a study reported from China; were cardiac complication was a 217 statistically significant predictor of mortality among ESRD patients(16). Similarly, we 218 found a cumulative hazard of mortality that was three times among patient with CVD 219 complications it has been reported that stroke was a prominent predictor of all-causes 220 of mortality in patients who had cardiovascular complications (16). The burden of 221 chronic kidney disease on mortality is significant and continues to increase, which 222 requires, optimal medical management. Studies reported the excess of cardiovascular 223 morbidity and mortality in patients with renal insufficiency particularly (17).

224 The risk of death for ESRD patients with infection was about three times higher than 225 that than of the patients on hemodialysis without infection. Similar study in Ethiopia 226 found a risk of death in patients in maintenances hemodialysis with septicemia which 227 accounts for 34.1% of all-cause of mortality (5). Another study from Taiwan found a 228 risk which is lower but in similar direction. Having infection and advanced CKD 229 increased the risk from all cause of mortality by 34% in the first year and 19% during 230 the nine years follow up period (18). Efforts at minimizing infectious complications, 231 preventing infection at any level should increase survival among hemodialysis patients.

232 In the present study, another factor that was identified as a predictor of mortality 233 among patients on hemodialysis was the type of vascular access for hemodialysis 234 treatment. Those who were on arteriovenous Catheter had a risk of mortality about four 235 times compared to those patients with AFV access. This result is consistent with a study 236 reported in Iran a 3.6-fold higher risk of death (19). This study showed that a vascular 237 access using catheter accompanied with increased risk of death and this is highly likely 238 as the fact that. In fact, limiting the use of catheters minimized the infection 239 complications in patients.

Another two studies show that catheter use was associated with a mortality risk of 67%
and three times as compared with use of an AVF(17). We similarly found a risk of
mortality of about 47% higher among patients who used Catheter.

Dissimilar to our result a retrospective cohort study in Belgium found a vascular access
type was not independently correlated with patient survival, even after taking into
account change of vascular access over time(20). And also the result of this study is

246 consistent with nighty one hemodialysis case summary of hemodialysis patents in 247 Ethiopia revel that patients who had catheter as permanent vascular access was 248 associated with poor outcome as compared to artery venous fistula and Graft and one-249 year survival rate for AVC group were 5.4 % and 66.9 % in other types of vascular 250 access( p-value <0.0001)(5). In summary most of studies found that Arteriovenous 251 catheter increases the risk of death compared to other vascular access. This might be 252 due to a high risk of infection in patient taking treatment by AVC.

- 253 Hypertension were another significant predictor of mortality in risk of having that was 254 four times. High blood pressure in our analysis was associated with a mortality risk of 255 four times and this is inconsistent with studies that found reverse association i.e., high blood pressure associated with low risk and low blood pressure associated with high 256 257 risk of mortality in dialysis patients. Contradict to this study some of the existing studies refer to this phenomenon as "reverse epidemiology", indicating a paradoxical 258 259 association between mortality and the effect of hypertension in dialysis patients. This 260 paradoxical phenomenon of lower BP or a decline in BP over time is associated with 261 increased mortality and higher BP is associated with lower mortality is described as 262 "reverse" epidemiology of hypertension (21).
- 263 There are several possible explanations for this finding in the literature, for instance, 264 discrete (binary) categorization of hypertension at the baseline as (yes or no) instead of 265 using blood pressure as a continuous variable (SBP, DBP). Binary categorization of 266 hypertension indeed did not reveal how severe it was at the baseline. This 267 categorization, due to insufficient information on blood pressure measurements, and 268 duration of antihypertensive medication use or any relevant treatment at the baseline 269 could have resulted in reporting normotensive or well-controlled hypertension patients 270 as hypertensive. Similar to our study, an Indonesian finding found a high blood pressure 271 that associated with a high risk of mortality though the risk is low compared to our 272 study (15).
- 273 Overall, this study can provide preliminary information about predictors that affect 274 survival status of CKD patients on hemodialysis in the three selected hemodialysis 275 centers in Addis Ababa, Ethiopia. Since we have limited information about this topic our 276 study would have paramount importance in recognizing the problems and complication 277 in hemodialysis patients. However, due to limited sample size of the study we might not

confidently rely on this information and we recommend further investigation by
overcoming the apparent limitation of this study. Being a retrospective study we were
unable to find some important predictors that should be considered in the study leaving

a question of potential residual confounding bias.

## 282 Conclusions

The survival status of hemodialysis patients in the three hospitals was low. Preventing and treating comorbidities and complications during dialysis would reduce the mortality of CKD patients.

## 286 Funding

287 Self-sponsored.

## 288 Computing interest

289 The authors declare that not have conflict of interest

## 290 Ethics approval and consent to participate

Ethical clearance was obtained from the Ethical Review Committee of Debre Berhan University, College of Health Sciences (Protocol number: 12/21/CHS/SPH). Permission was obtained from all Hospitals and dialysis Centers. Confidentiality and privacy of the information were assured and maintained by preventing disclosure of the information to third parties.

## 296 Acknowledgements

The authors give extended gratitude to Debre Berhan University College of Health Sciences, Department of Public Health for providing the golden opportunity to carry out this study, all staff members of SPHMMC, ZMH, MRH, Data collectors, family and friends who supported in all efforts to accomplish the study.

## 301 **References**


302 [1. Jha V, Garcia-garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Global Kidney


303		Disease 3 Chronic kidney disease : global dimension and perspectives. Lancet
304		[Internet]. 2013;382(9888):260–72. Available from:
305		http://dx.doi.org/10.1016/S0140-6736(13)60687-X
306	2.	Couser W, Remuzzi G, Mendis S, Tonelli M. The contribution of chronic kidney
307		disease to the global burden of major noncommunicable diseases. Kidney Int.
308		2011 Dec 1;80:1258–70.
309	3.	Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and
310		regional mortality from 235 causes of death for 20 age groups in 1990 and 2010:
311		A systematic analysis for the Global Burden of Disease Study 2010. Lancet.
312		2012;380(9859):2095–128.
313	4.	Sumaili EK, Krzesinski JM, Zinga C V., Cohen EP, Delanaye P, Munyanga SM, et al.
314		Prevalence of chronic kidney disease in Kinshasa: Results of a pilot study from the
315		Democratic Republic of Congo. Nephrol Dial Transplant. 2009;24(1):117–22.
316	5.	Shibiru T, Gudina EK, Habte B, Deribew A, Agonafer T. Survival patterns of
317		patients on maintenance hemodialysis for end stage renal disease in Ethiopia :
318		summary of 91 cases [Internet]. Vol. 14, BMC Nephrology. BMC Nephrology;
319		2013. 1 p. Available from: BMC Nephrology
320	6.	Lakshmi KR, Nagesh Y, Veerakrishna M. Performance Comparison of Three Data
321		Mining Techniques for Predicting Kidney Dialysis Survivability. Int J Adv Eng
322		Technol. 2014;7(1):242–54.
323	7.	Rezapour M, Zadeh MK, Sepehri MM. Implementation of Predictive Data Mining
324		Techniques for Identifying Risk Factors of Early AVF Failure in Hemodialysis
325		Patients. Hindawi Publ Corp. 2013;2013.
326	8.	Rezapour M, Taran S, Parast MB. The impact of vascular diameter ratio on
327		hemodialysis maturation time : Evidence from data mining approaches and
328		thermodynamics. MJIRI. 2016;
329	9.	Kore C, Tadesse A, Teshome B, Daniel K, Kassa A, Ayalew D. The Magnitude of
330		Chronic Kidney Disease and its Risk Factors at Zewditu Memorial Hospital, Addis
331		Ababa, Ethiopia. J Nephrol Ther. 2018;08(03):8–12.
332	10.	Collins AJ, Foley RN, Chavers B, Gilbertson D, Herzog C, Johansen K, et al. US renal
333		data system 2011 Annual data report. Am J Kidney Dis. 2012;59(1 SUPPL. 1):A7.
334	11.	Mekonen MW, Birahan KA, Chekole DM, Derso EA. Determinants of Overall
335		Survival of Kidney Failure for Patients Receiving Dialysis in Saint Geberial

336		General Hospital, Addis Ababa, Ethiopia. J Kidney OPEN. 2020;1–7.
337	12.	Berhanu G, Tibebu, Jelaludin Ahmed , Abebaw Ferede S, Negera A, Bezu HTA,
338		Kassie K narayana. UG, Abelti G, et al. Population Projections for Ethiopia. In:
339		Central Statistical Agency. 2013.
340	13.	Hussein M, Muleta G, Seyoum D, Kifle D, Bedada D. Survival Analysis of Patients
341		with End Stage Renal Disease the Case of Adama Hospital, Ethiopia Mekiya. Clin
342		Med Res. 2017;6(6):201–8.
343	14.	Lima JJG De, Sesso R, Abensur H, Lopes HF, Giorgi MCP, Krieger EM, et al.
344		Nephrology Dialysis Transplantation Predictors of mortality in long-term
345		haemodialysis patients with a low prevalence of comorbid conditions. Eur Dial
346		Transpl Assoc. 1995;1708–13.
347	15.	Urte Zakauskiene, Alvita Vickiene, Vaidas Vicka, Diana Sukackiene, Laurynas
348		Rimsevicius, Marius Miglinas. Institute of Clinical Medicine, Vilnius University
349		Faculty of Medicine V. E-POSTERS BLOOD PRESSURE DURING HEMODIALYSIS AS
350		PREDICTOR OF. Wolters Kluwer Heal. 2021;2021.
351	16.	Tong J, Liu M, Li H, Luo Z, Huang J, Liu R, et al. Mortality and Associated Risk
352		Factors in Dialysis Patients with Cardiovascular Disease. kidney internatonal.
353		2016;479–87.
354	17.	Astor BC, Eustace JA, Powe NR, Klag MJ, Fink NE. Type of Vascular Access and
355		Survival among Incident Hemodialysis Patients : The Choices for Healthy
356		Outcomes in Caring for ESRD ( CHOICE ) Study. Am Soc Nephrol. 2005;1449–55.
357	18.	Chang C, Fan P, Kuo G, Lin Y, Tsai T. Infection in Advanced Chronic Kidney Disease
358		and Subsequent Adverse Outcomes after Dialysis Initiation : A Nationwide Cohort
359		Study. Sci Rep [Internet]. 2020;1–10. Available from:
360		http://dx.doi.org/10.1038/s41598-020-59794-7
361	19.	Salman Khazaei MY, Nematollahi1, ShahrzadZobdeh2, ZahraSheikh3,
362		VidaMMansournia ohammad A. Survival Rate and Predictors of Mortality among
363		Hemodialysis Patients in West of Iran , 1996 – 2015. Int J Prev Med  . 2018;1–5.
364	20.	Clerck D, Bonkain F, Cools W, Niepen P Van Der. Vascular access type and
365		mortality in haemodialysis : a retrospective cohort study. BMC Nephrol. 2020;1–
366		7.
367	21.	Georgianos PI, Agarwal R. Blood Pressure and Mortality in Long-Term
368		Hemodialysis — Time to Move Forward. Am J Hypertens. 2017;30(March):211-

- 22.

#### **Figure legends** 375





381 Figure 1: Kaplan-Meier survival curves for hemodialysis patients, according to the mean of the covariate of 382 139 patients diagnosed in 2016-2020 in, Addis Ababa Ethiopia.

#### Tables

#### Table 1: Socio Demographic characteristics of 139 ESRD patients on maintenance

hemodialysis for in Addis Ababa Ethiopia, from January 1st 2016 to December 31st 2020

Characteristic		Frequency(n)	Percentage
Age (mean ±SD	18-34	77	55.4
(35.81±11.9)	35-54	48	34.5
	≥55	14	10.1
Gender	Male	88	63.3
	Female	51	36.7
Occupation	Government	25	18.0
	Private	30	21.6
	Unemployed	57	41.0
	Farmer	1	0.7
	Student	6	4.3
	Not recorded	20	14.4
Residence	Addis Ababa	102	73.4
	Out of Addis	37	26.6
	Ababa		
Marital status	Single	59	42.4
	Married	75	54.0
	Divorced	3	2.2
	Widow	2	1.4

#### Table 2: Base line data blood pressure and weight with their statistical parameter

- ESRD patients on maintenance hemodialysis for in Addis Ababa Ethiopia, from
- January 1st 2016 to December 31st 2020

Base line data	Mean	Median	Standard	Range	Minimum	Maximum
of the patient			division			
Systolic	143.95	140	21.935	129	92	221
BP(first)						
Diastolic BP	87	90	14.941	73	53	126
(first)						
Systolic	142.1	140	19	99	95	194
BP(last)						
Diastolic	84	86	13	86	44	130
BP(last)						
Weight (first)	55.54	54	11.42	56.1	31.8	87.9
Weight(last)	54.9	53	10.99	57	30	87

#### 415 **Table 3: Patient Laboratory value with their statistical parameter ESRD patients**

#### on maintenance hemodialysis for in Addis Ababa Ethiopia, from January 1st 2016 416 417 to December 31st 2020

Serum electrolyte	Mean	Median	Standard	Range	Minimum	Maximum
(first and last)			deviation			
Creatinine(mg/dl)	8.9	8.6	3.55	18.0	2	20.04
Hemoglobin	10.37	10.1	2.27	11.1	5	16.1
Hematocrit	31.81	6.98	43	32	15.8	47.8
Phosphorus	2.21	1.7	1.59	7.47	0.43	7.9
Potassium	4.83	4.92	1.0	6.97	0.85	7.82
Calcium	3.39	2.23	2.4	8.7	0.92	9.61
Albumin	3.86	3.9	0.8	4.8	2.1	6.9
Sodium	136.7	138	6.59	48	99	147
Urea	104.2	96.8	46.1	202.6	10.4	213
Creatinine(mg/dl)	5.14	4.32	3.03	14.0	0.6	14.6
Hemoglobin	10.2	10.2	1.87	10	5	15
Hematocrit	31.35	31	6.12	32.5	15	47.5
Phosphorus	2.0	1.7	1.3	7.9	0.52	8.3
Potassium	4.95	4.9	0.99	4.8	2.9	7.7
Calcium	3.65	2.4	2.6	9.2	1.2	10.4
Albumin	3.5	3.5	0.54	3.0	2	5
Sodium	137.3	137.0	4.14	22	127	149
Urea	57	46	39	158.75	5.25	16.4

418 Table 4: Treatment modalities for 139 ESRD patients on maintenance

419 hemodialysis for in Addis Ababa Ethiopia, from January 1st 2016 to December 31st 2020 420

Variables Characteristic N (%) Percentag e Frequency of dialysis 15 Twice 10.8 session/week Three 124 89.2 Duration of dialysis Three hours 5 3.6 per session Three and half hours 13 9.4 Four hours 121 87

Types of vascular	Catheter	50	36
access	Arteriovenous fistula	88	63.3
	Arteriovenous graft	1	0.7
Cause of CKD	Hypertension	67	48.2
	Diabetes mellitus	9	9
	Glomerulonephritis	9	9
	Renal stone	3	3
	Unknown	51	51
Blood transfusion	Yes	24	17.3
	No	115	82.7
EPO treatment	Yes	124	89.2
	No	15	10.8
Cause of death	Cardiovascular disease	6	25
	Infection	4/24	16.7
	Uremic complication	3/24	12.3
	Sudden death	4/24	16.7
	Hyperkalemia	1/24	4.1
	Cardiac arrest	2/24	8.3
	Cardiovascular disease	4/24	16.7

421

422

#### 423 Table 5: patient status for 139 ESRD patients on maintenance hemodialysis for in Addis Ababa Ethiopia, from January 1st 2016 to December 31st 2020 424

Variable	Category	Total (%)	Number of	Censored (%)
			event (%)	
Sex	Male	88(63.3)	15(17)	73(83)
	Female	51(36.7)	9(17.6)	42(82.4)
Resident	Addis Ababa		19(18.63)	83(81.37)
		102(73.4)		
	Out of Addis	37(26.6)	5(13.51)	32(86.49)

Marital status	Married	75(54.7)	12(16)	63(84)
	Unmarried	63(43.3)	12((19)	51(81)
Vascular access	AVF	88(63.3)	6(6.8)	82(93.2)
	Catheter	50(36)	17(34)	33(66)
	Graft	1(0.7)	1(100)	0(0)
Frequency of	Twice per week	15(10.8)	7(46.7)	8(53.3)
dialysis per week	Three per week	124(89.2)	17(13.7)	107(86.3)
Duration of	Three hours	5(3.6)	2(40)	3(60)
dialysis	Three and half hour	13(9.4)	4(30.8)	9(69.2)
	Four hours	121(87)	18((14.9)	10385.1)
Hypertension	Yes	96(69)	22(23)	74(77)
	No	43(31)	2(4.65)	41(95.35)
Diabetes mellitus	Yes	11(7.9)	3(27.3)	8(72.7)
	No	128(92.1)	21(16.4)	107(83.6)
albumin(mg/dl)	Under 3.5	57(41)	18(31.6)	39(68.4)
	3.51-4.00	45(32.4)	2(4.4)	43(95.6)
	Above 4.01	37(26.6)	4(10.8)	33(89.2)

Table 6: unadjusted survival HR (95% CI) of ESRD patients on maintenance

hemodialysis for in Addis Ababa Ethiopia, from January 1st 2016 to December 

31st 2020

Variable	Category	p-value	Crude HR (95%CI)
	Yes	0.047	4.331(1.018-18.431) *
Hypertension	No*		1
Types of vascular access	Graft	0.036	10.069(1.166-86.976)
	Catheter	.000	9.479(3.558-25.24) ***
	Fistula*		1
Infection	Yes	0.038	3.625(1.071-12.255) *

	[		1	1.
		No*		1
	Cardiovascular	Yes	0.015	4.495(1.338-15.105) *
	complication			
		No*	_	1
	Frequency of dialysis per	Two times		2.7(1.116-6.533)
	week		0.28	
		Three times*	-	1
	The reference categories w	vere those indicate	ed in asterisk (	*)
433	*Significant (P-value < 0.0	5), **significant (p	o-value<0.01) a	and*** significant (p<0.001)
434	CHR: - Crude Hazard Ratio	, AHR: - Adjusted I	Hazard Ratio, H	IR=1 is reference variable.
435				
436				
437				
438				
439				
440				
441				
442				

#### 443 Table 7: adjusted survival HR (95% CI) of ESRD patients on maintenance

#### 444 hemodialysis for in Addis Ababa Ethiopia, from January 1st 2016 to December

445 31st 2020

Variable	Category	p-value	Unadjusted HR (95%CI)
	Yes	0.015	7.139(1.474-34.565)
Hypertension	No*	-	1
Types of vascular access	Graft	0.010	19.568(2.008-190.736)
	Catheter	0.09	3.839(1.404-10.498)
	Fistula*		1

It is ma	ade available unde	ir a	CC-BY	<b>4.0</b>	International	license .

Infection	Yes	0.035	3.586(1.985-13.054)
	No*		1
Cardiovascular complication	Yes	0.017	4.696(1.316-16.763)
	No*		1
The reference categor	ries were those in	dicated in asteris	k (*)

- 446 NB: \*Significant (P-value < 0.05), \*\*significant (p-value<0.01) and \*\*\* significant
- 447 (p<0.001) CHR: Crude Hazard Ratio, AHR: Adjusted Hazard Ratio, HR=1 is reference
- 448 variable.